Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
about
Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotypingMurine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphomaStereotyped patterns of B-cell receptor in splenic marginal zone lymphomaSplenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis.Laparoscopic splenectomy for treatment of splenic marginal zone lymphomaDefining the borders of splenic marginal zone lymphoma: a multiparameter study.Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological featuresMolecular characterization of the region 7q22.1 in splenic marginal zone lymphomas.Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting ManifestationThe NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.Epidemiology, pathology and treatment of non-follicular indolent lymphomas.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients.Hairy cell leukemia-new genes, new targets.Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Splenic marginal zone lymphoma: disease features and management.Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: A single-centre analysis.Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node.Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study.Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphomaSplenic marginal zone lymphoma: hydra with many heads?Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use.The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
P2860
Q24628943-ED859F04-DA35-44F1-A6BA-9910E0570598Q28070123-1F38B1E7-B292-47E7-8982-1DA99C8BCBFEQ28537689-F00C6641-FB3B-4980-B0C8-8DF0D9EAB32AQ29048186-79E9CDA6-F904-4598-9894-D184A31983D5Q30275946-03FFDCC6-E283-472A-84A3-4DC1390091CDQ33409008-FA46EDE1-7E2C-45CA-B439-DE8349462D81Q33890663-630D06CB-F4D8-4CA4-8943-5F3DAC48D4D3Q33952773-FF7DD7E2-84F3-417D-9DD3-568028420430Q34034713-A4B21C9E-D321-4A77-B4ED-6476A8876E69Q34252178-7A9C7EE7-E59A-4626-8EF0-6506E73D3958Q34387911-324E8E09-C865-4D28-BED2-4C24A8AD1496Q35001307-63E4D98F-69E5-4213-AB6B-BC28E8B2E6EBQ35002178-DF537E53-2FDC-4B28-A958-4A6ACAFAED45Q35561291-808F268A-EF15-41E0-8122-F23EEE0A1CC4Q35720912-014B180C-B16A-4C0B-A76D-068077140236Q35812737-CFD1C1A2-C0D5-40A7-A94C-10DAE8C2C2ECQ36193517-7FB76D1B-5ED9-4039-94F0-7A175090EB65Q36630461-531EE11B-2094-41CE-A35C-5CBE970523ADQ36779686-30C16593-AAEA-4143-8CE2-050A2CC8CF42Q36932991-21183AF1-B32D-470E-9FA3-7BBFB29AB544Q37201887-036EF510-4E74-4695-8C98-CBDC8614879BQ37280928-9F3ECAC5-EDF1-460E-A607-C493B51BD4A3Q37364653-94E8882E-A444-4AA0-8BBE-3A5915E0661CQ37726667-614DAE23-92DE-40D9-A10A-0C0BB46F7794Q38124726-EEEF8BC5-5110-4D67-9579-247A219C6136Q38139569-4D53BEC2-BB67-40F7-8760-56050EBB8C6DQ38156238-51C56C35-513F-4760-9C06-034E7B77C776Q38650484-47BCAA1E-D214-409F-AFCC-DD0167B3344CQ39347902-E4D7F9E7-C21A-4676-81CE-55DB2B0E1F4DQ41047306-0C3C264D-ED58-4212-A799-2803C60FAD15Q41407104-D1AA7680-0AAF-48C2-B9FC-968307F61515Q42256967-4DB0FDE0-12E9-4F54-B945-028F9118906FQ42277969-C5AA315D-19FD-4A53-9ECC-64D8AC107381Q42341705-B6477AC8-DC03-4155-987C-3DD8EBE6FE43Q42353159-8F946498-D149-49EB-AA24-FD430850C74FQ42832521-74B642EB-2FEB-42AD-996A-6BECB8DF19FCQ43743732-5AAF795A-5C0A-43C9-9392-4D0E24CBD34FQ43854217-4E90392E-E3D4-464C-94BF-0DBFEA8936F1Q44133528-1B9109D7-C802-4845-9FD9-542832D83534Q44628624-70786CA4-A198-4A6D-AE10-314E259E00FF
P2860
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@en
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@nl
type
label
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@en
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@nl
prefLabel
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@en
Splenic marginal zone lymphoma ...... ging and therapeutic criteria.
@nl
P2093
P2860
P356
P1433
P1476
Splenic marginal zone lymphoma ...... aging and therapeutic criteria
@en
P2093
Callet-Bauchu E
Coiffier B
Iannitto E
Montalban C
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405068
P577
2007-12-20T00:00:00Z